# UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients

> **NCT05682586** · PHASE3 · UNKNOWN · sponsor: **Shanghai East Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Mesenchymal Stem Cell
- COVID-19 Pneumonia

## Interventions

- **BIOLOGICAL:** umbilical cord mesenchymal stem cells
- **DRUG:** paxlovid

## Key facts

- **NCT ID:** NCT05682586
- **Lead sponsor:** Shanghai East Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-09
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-07-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05682586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05682586, "UC-MSCs in the Treatment of Severe and Critical COVID-19 Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05682586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*